Business description: Ovoca Bio plc

Ovoca Bio PLC is a clinical-stage biopharmaceutical company focused on women’s health. The Company is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). It is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain. It is also developing a new treatment for women affected by low libido or sex drive. It owns a patent portfolio that provides effective protection of its technology. The Company operates in Ireland, the United Kingdom and Russia.

Bio Therapeutic Drugs

Change 5d. change 1-year change 3-years change Capi.($)
-0.36%-1.35%+11.40%+85.44% 42.98B
-1.13%-2.60%+42.18%+15.00% 39.24B
-0.01%-0.45%+82.23%+661.46% 30.07B
+1.21%-10.16%-8.32%-30.06% 21.88B
-1.71%-5.01%+29.53%-30.75% 18.25B
-2.18%-1.50%+20.40%-32.01% 16.03B
-0.81%+2.70%+53.06%+171.76% 12.97B
+4.27%+6.68%-22.46%+826.44% 12.5B
+1.75%+2.23%+58.17% - 11.76B
Average +0.11%-0.79%+29.58%+208.41% 22.85B
Weighted average by Cap. -0.18%-1.33%+31.08%+180.37%
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW